Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2024-08-28 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司关于使用部分闲置募集资金进行现金管理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 奥锐特药业股份有限公司 regarding the use of part of idle raised funds for cash management. It details the amount, purpose, risk, and approval process related to the use of idle raised funds for investing in low-risk financial products. The document references regulatory approvals, board and supervisory committee meetings, and compliance with listing rules. It does not contain financial statements or detailed financial results but is a regulatory disclosure about the company's use of raised funds. The document length is 3884 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about the use of funds, not a full financial report or earnings release.
2024-08-28 Chinese
奥锐特药业股份有限公司关于部分董事减持股份计划公告
Director's Dealing Classification · 95% confidence The document is a formal announcement regarding a planned reduction in shareholding by a company director, including details about the number of shares to be sold, the reasons for the sale, compliance with regulatory requirements, and risk disclosures. It does not contain financial statements, earnings data, or detailed management discussion. It is a notification about a director's personal share transactions (share reduction) and related compliance information. Therefore, it fits the category of Director's Dealing (DIRS). The document length is under 5,000 characters and is a detailed announcement, not a brief report publication notice or a regulatory filing. Hence, the classification is DIRS with high confidence.
2024-08-19 Chinese
奥锐特药业股份有限公司向不特定对象发行可转换公司债券上市公告书
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the issuance and listing of Aurisco Pharmaceutical Co., Ltd.'s convertible corporate bonds. It includes extensive information about the bond issuance, terms, underwriting, credit rating, use of proceeds, and company background. The document is titled as a "上市公告书" (Listing Announcement) for convertible bonds and contains no financial statements or quarterly/yearly financial results. It is not an earnings release, annual report, or interim report. It is a formal announcement related to capital market activity, specifically the issuance and listing of convertible bonds. This fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance terms and conditions, confirming it is not a mere announcement of a report but the actual issuance document. Therefore, the classification is CAP with high confidence.
2024-08-12 Chinese
奥锐特药业股份有限公司关于签署募集资金专户三方（四方）监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the signing of supervision agreements for the special accounts holding funds raised from a convertible bond issuance by 奥锐特药业股份有限公司. It details the amount raised, the parties involved in the supervision agreements, the purpose of the funds, and the regulatory compliance measures. The document does not contain financial statements or detailed financial performance data but focuses on the management and supervision of raised capital. The length is under 5,000 characters and it is an announcement about fundraising and capital management rather than a full financial report or audit. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-08-08 Chinese
奥锐特药业股份有限公司向不特定对象发行可转换公司债券发行结果公告
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the issuance results of convertible bonds by 奥锐特药业股份有限公司. It details subscription quantities, underwriting, and allocation results, including dates and amounts. The content focuses on the outcome of a financing activity, specifically the issuance of convertible bonds, and does not contain financial statements or quarterly/yearly performance data. It is not a full financial report, earnings release, or regulatory certification. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is a direct announcement of issuance results, not a report publication announcement or regulatory filing.
2024-07-31 Chinese
奥锐特药业股份有限公司向不特定对象发行可转换公司债券网上中签结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement of the lottery results for the online subscription of convertible bonds issued by the company 奥锐特药业股份有限公司. It details the winning numbers and the number of winning subscriptions. This is an update related to the company's financing activities, specifically the issuance of convertible bonds. It is not a full financial report, earnings release, or management discussion. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on the financing event, confirming the classification.
2024-07-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.